The FDA has introduced a faster review process for nicotine pouch applications in the United States.
Although it is often described as a "fast-track" system, it is officially a pilot program designed to increase efficiency and streamline reviews of Premarket Tobacco Product Applications (PMTAs) for nicotine pouches. It is not the same as the FDA's formal Fast Track designation used for pharmaceutical drugs.
The goal is to make nicotine pouch reviews faster and more efficient without lowering the scientific standards required for marketing authorization.
How Does It Work?
Nicotine pouch manufacturers still need to submit a PMTA and receive FDA marketing authorization for a new product to be lawfully marketed in the United States.
The FDA evaluates factors including:
- product chemistry and toxicology
- nicotine delivery and exposure
- potential use by adults, youth and non-users
- whether adult tobacco users may switch from more harmful products
- the product's overall impact on public health
Under the pilot program, the FDA communicates more directly with applicants during the review process. Questions, missing information and requests for clarification can be addressed earlier, with the aim of reducing delays and limiting the number or severity of issues in formal deficiency letters.
The Pilot Is Already Producing Results
The first decisions under the pilot included six on! PLUS nicotine pouch products. The FDA said the scientific review was completed in record time.
On August 21, 2026, the agency also authorized 11 ZYN ULTRA products through the PMTA pathway.
As of August 21, 2026, the FDA reported that 43 nicotine pouch products had received marketing authorization, with 23 of those authorizations coming from applications reviewed as part of the pilot program.
The FDA has also authorized a ZYN ULTRA product containing 11 mg of nicotine per pouch. This does not mean nicotine strength is irrelevant. Rather, the FDA says nicotine exposure is evaluated as part of the product's overall risk and benefit assessment, alongside its design, formulation, materials and nicotine delivery characteristics.
FDA Authorized Is Not the Same as FDA Approved
This distinction is important.
Nicotine pouches that receive a Marketing Granted Order are authorized for marketing. They are not "FDA approved" in the same way as medicines.
The FDA continues to state that tobacco products are not safe or risk-free and that nicotine is addictive. At the same time, the agency recognizes differences in risk between tobacco products. The FDA states that non-combusted tobacco products, including authorized nicotine pouches, can generally pose lower health risks than combustible cigarettes.
For adults who currently smoke or use more harmful tobacco products, the potential benefit of completely switching to a lower-risk product is part of the FDA's population-level assessment.
What About Products Still Pending Authorization?
In May 2026, the FDA also issued guidance on enforcement priorities for certain unauthorized nicotine pouch products.
Under that policy, the FDA generally does not intend to prioritize enforcement against certain products with pending PMTAs that have been accepted and filed, subject to the conditions described in the guidance.
This is not marketing authorization. The FDA explicitly states that a product falling within the enforcement policy does not indicate that it is likely to receive authorization.
What Does This Mean for the Nicotine Pouch Industry?
The pilot could represent a significant shift for the US nicotine pouch market.
Manufacturers with strong scientific evidence may be able to receive regulatory decisions more efficiently, while the FDA continues enforcement efforts against products operating outside the PMTA framework.
The direction is becoming clearer: the FDA is willing to authorize individual nicotine pouch products when the evidence shows that the potential benefits to the population, including benefits for adults switching from more harmful tobacco products, outweigh the risks, including risks to youth and non-users.
The nicotine pouch pilot does not remove the PMTA requirement or guarantee authorization. What it does provide is a faster and potentially more efficient regulatory review process for a category the FDA increasingly evaluates through a relative-risk framework.
Sources
- FDA: Launches Program to More Efficiently Review Nicotine Pouch Applications, September 18, 2025
- FDA: Authorizes 6 Nicotine Pouch Products, Completing Review in Record Time
- FDA: Authorizes 11 New Nicotine Pouches, August 21, 2026
- FDA: Nicotine Pouch Products Authorized by the FDA
- FDA: Enforcement Priorities for Unauthorized ENDS and Nicotine Pouch Products, May 8, 2026
Last updated September 2026. This article is for informational purposes and does not constitute legal advice.
Share: